GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Aytu BioPharma Inc (LTS:0A8M) » Definitions » Net Intangibles Purchase And Sale

Aytu BioPharma (LTS:0A8M) Net Intangibles Purchase And Sale : $0.00 Mil (TTM As of Mar. 2025)


View and export this data going back to 2021. Start your Free Trial

What is Aytu BioPharma Net Intangibles Purchase And Sale?

Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

Aytu BioPharma's net Intangibles purchase and sale for the three months ended in Mar. 2025 was $0.00 Mil. Its net Intangibles purchase and sale for the trailing twelve months (TTM) ended in Mar. 2025 was $0.00 Mil.

Aytu BioPharma Net Intangibles Purchase And Sale Historical Data

The historical data trend for Aytu BioPharma's Net Intangibles Purchase And Sale can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aytu BioPharma Net Intangibles Purchase And Sale Chart

Aytu BioPharma Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Net Intangibles Purchase And Sale
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Aytu BioPharma Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Net Intangibles Purchase And Sale Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Aytu BioPharma Net Intangibles Purchase And Sale Calculation

Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

Net Intangibles Purchase And Sale for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aytu BioPharma Net Intangibles Purchase And Sale Related Terms

Thank you for viewing the detailed overview of Aytu BioPharma's Net Intangibles Purchase And Sale provided by GuruFocus.com. Please click on the following links to see related term pages.

Aytu BioPharma Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Aytu BioPharma Inc (LTS:0A8M) » Definitions » Net Intangibles Purchase And Sale
Comparable Companies
TLPH RSCI FLGC YCBD BIOE TXMD DRRX CPHI GELS LVRLF ZTS XTER:MRK LSE:HLN NSE:SUNPHARMA TSE:4502 XSWX:GALD XSWX:SDZ NSE:DIVISLAB HKSE:03692 XTAE:TEVA
Traded in Other Exchanges
AYTU:USA
Address
7900 East Union Avenue, Suite 920, Denver, CO, USA, 80237
Website
https://www.aytubio.com
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates in two segments Rx Segment, consisting of prescription pharmaceutical products and Consumer Health segments of which the company generates maximum revenue from the Rx segment.

Aytu BioPharma Headlines

No Headlines